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EDITORIAL

Proteomics in CKD: The Young Man and the ‘‘See’’

H

emingway’s 1952 Pulitzer Prize-winning novella,
The Old Man and the Sea,1 described the physically
rigorous but simple Cuban fishing method of yore used
by protagonist Santiago during his 3-day ordeal with a giant marlin. In the end, Santiago is declared triumphant,
despite the loss of the greatest ‘‘catch’’ of his life. The
inspired dedication exemplified by Santiago has been
mirrored by protein chemists for decades. These men of
science clearly understood that analyzing, categorizing,
and characterizing the end-product of a gene, the protein,
were and would be critical to several disciplines, including medicine. However, for sometime, the alpha-toomega relationship of gene-to-protein was reversed and
all biological buzzwords began with ‘‘gene or genomic.’’
In ‘‘Revolution Postponed,’’ Stephen S. Hall notes that
the Human Genome Project had not yet attained those
miracles of medicine,2 so desperately awaited during
the frenzied period marked by the sequencing of human
DNA. Notwithstanding the numerous advances brought
forth by the substantial efforts of many researchers
during this epochal phase of fundamental biology,
another field increasingly emerged and with less fanfare:
proteomics, the study of the proteome. This portmanteau
of proteins and genome represents the large-scale description of the complement of proteins expressed by a cell,
organ, or organism, during a defined period or set of
conditions. In the domain of nephrology, proteomics
may reflect the unique protein signatures that appear in
the plasma or urine during normal kidney health or
during its derangement(s) by any one of various causes
and conditions.
The proteome in human beings is much smaller in
number than the putative number of genes, by approximately two orders of magnitude, as only 1.5% of the genome is transcribed and translated to proteins. We have
witnessed this disparity in the past. Previously, we posited
that our immunological system, to afford protection and
competence, was of necessity and required to recognize
approximately million antigens. Correspondingly, there
was a requirement for production of the same number of
different antibodies, thereby directing the bulk of meta-

bolic activities to that end. Presently, we know better
and acknowledge that sophisticated intracellular and molecular processing derivatizes many foreign antigens into
simpler and more fundamental units for antigen presentation that are dealt with by far fewer antibodies. Essentially,
nature evolved and adapted a modular approach, thereby
providing itself efficiency and throughputness. As Einstein put it, nature made things simpler but not simple.
The same is true of proteins, wherein a particular proteome as a module, give or take a few proteins, may satisfy
a host of biological requirements. Conversely, the lack of
vital components of a proteome may render an organism
ill-equipped to handle a particular group or set of
stressors.
Proteomics has advanced remarkably in the past decade and nearly every major university maintains a proteomics core laboratory. This field has been enhanced by
the ultrafine specificity intrinsic to its methodology of
separative analysis. Two-dimensional gel electrophoresis, combining resolution of proteins by charge and
mass, identifies protein identities on the basis of their respective, unique, migratory patterns and helps determine
the proteome.3 This technique is highly synergized and
automated by mass spectrometry (MS) and peptide
mass fingerprinting, which is aided and abetted by powerful bioinformatical databases. MS, commonly used by
analytical laboratories, characterizes the physical, chemical, and biological properties of many compounds and is
available in a variety of forms, including time of flight,
quadrupole mass filter, and orbitrap, among others. Another method, tandem MS sensitively and specifically
determines individual sequence information at the
peptide-level, comparing fragment ion profiles generated
by colliding peptides in a nonreactive gas. Furthermore,
peptidomic analysis may render insights into treatment
efficacy: one peptidome may predict a positive response
to a prescribed therapy, whereas another may
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differentiate an intermediate or null response.4 Such
differential responses may greatly precede any clinical
measurement(s), and may be of extreme importance
when a given treatment is potentially toxic.
In this year-end issue of Advances in Chronic Kidney
Disease, we fix our diagnostic and therapeutic gaze
toward 2011 and beyond. As such, we have enlisted the
efforts and visions of 2 Guest Editors and proteomics
experts, Dr. Jonathan Klein, M.D., Ph.D., University of
Louisville School of Medicine, and Dr. John Arthur,
M.D., Ph.D., Medical University of South Carolina. The
Guest Editors have in turn chosen contributors who
will provide the underpinnings of the array of opportunities that proteomics parlays in CKD, in terms of
diagnostics and therapeutics. To this end, this compilation focuses primarily on expression and functional
proteomics rather than structural proteomics.
Dr. Klein elucidates the nephropathic proteome of diabetes. Here, the fundamental realism of biomarkers will be
understood and provide a prototype for Dr. Yamamoto’s
characterization of CKD as a series of enlarging proteomic
databases. The unions and intersections of these bioinformatic repositories represent a nexus of knowledge for
many disease states, not just renal ones. The acquisition
speed of such knowledge occurs at breathtaking speed
and is now at the end-user level. No supercomputer required! Dr. Mischak describes the urinary proteome of
CKD, a novel form of urinalysis—indeed, a biomolecular
biopsy of the kidney that begs for clinical correlation and

begets directed therapy. Dr. Merchant expands on the
uses of MS in kidney research and finally, Dr. Devarajan
describes the use of targeted kidney biomarkers in CKD,
today and in the future.
Therefore, and not too futuristically, applied proteomics provides disease detection at the asymptomatic
disease phase and quantitative treatment timing and directionality, which is presently impossible to achieve by
contemporary clinical and imaging technologies. In conclusion and on reflection, I recall the time when I was
much younger and thinking that our future would be revealed as deoxyribonucleic acid was unwound and decoded, this aspiring nephrologist- and physiologist-to-be
was presagingly, albeit clairvoyantly, informed by a wiser
and more experienced mentor, ‘‘Young man, in the end,
you’ll see . it’s in the proteins.’’ And, it is.
Jerry Yee, MD
Editor
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